ORLANDO, Fla.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today reported the final results of a Phase III study comparing VELCADE® (bortezomib) for Injection and rituximab to rituximab alone for the treatment of patients with relapsed or refractory follicular lymphoma (FL) who were rituximab-naïve or -sensitive. These data were presented at the 52nd annual meeting of the American Society of Hematology (ASH), held December 4-7 in Orlando, Florida.
